Loading...
In patients with non–ST-segment elevation myocardial infarction (NSTEMI), the factor Xa inhibitor fondaparinux was noninferior to enoxaparin in reducing ischemic outcomes in the OASIS-5 study. In addition, fondaparinux reduced severe in-hospital bleeding events, leading to both short- and long-term mortality reductions. To see how these trial findings translate to clinical practice, researchers conducted a prospective, multicenter cohort study in Sweden, analyzing data from 40,616 consecutive patients with NSTEMI (mean age, 73 years; 37% women) in the SWEDEHEART registry. Data were from a 4.5-year period spanning the European Society of Cardiology guideline adoption of fondaparinux as the first-line anticoagulant for NSTEMI patients in 2007…